We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Trellus Health Plc | LSE:TRLS | London | Ordinary Share | GB00BNNFM402 | ORD GBP0.0006 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.95 | 0.90 | 1.00 | 0.95 | 0.94 | 0.95 | 55,802 | 08:00:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Offices Of Medical Doctors | 19k | -6.34M | -0.0392 | -0.24 | 1.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/8/2022 17:11 | Notable volume today. | wan | |
13/8/2022 11:26 | I also meant to add that EKF indicated their intention to launch a Calprotectin test this year. Fecal calprotectin (or faecal in the UK), is a marker of mucosal inflammation. The test can help physicians diagnose inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and differentiate them from irritable bowel syndrome (IBS). Going forwards, Trellus intend to also address IBS, and I note a test for this is included in the indicated list of tests at EKF owned ADL Health laboratory in the US. | wan | |
13/8/2022 11:06 | I note recently that some large players are actively interested or indeed already moving into the area of addressing chronic conditions. I also note the following - Congratulations from the entire Trellus community to our co-founder, Dr. Laurie Keefer for receiving the Distinguished Investigator Award for Women in Neurogastroenterolog Recall that in September 2021 Trellus signed an agreement to provide an Inflammatory Bowel Disease ("IBD") demonstration programme for the Mount Sinai Health System. Following enrolment, the demonstration programme will coordinate six months of active care management followed by a final programme report, expected to be available within 30 days of programme completion. This initial demonstration programme is expected to commence before the end of 2021 with conclusions from the final programme report expected in 2022. One would assume that that final programme report must be getting quite close to publication. | wan | |
01/8/2022 07:51 | Trellus not intending to sit on their laurels either though with todays announcement. | wan | |
30/7/2022 05:30 | I note the large volume yesterday. | wan | |
27/7/2022 10:34 | Edit to the above post - In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards. | wan | |
27/7/2022 10:24 | I would also add that the market backdrop has resulted in many valuations being significantly reduced, and will mean that affected companies, especially those such as Trellus with 'scientifically validated' methods delivered by technology, are likely to come on to certain radars. In Trellus's case, there is the potential from companies looking to pivot, or pivot further, into chronic disease management, either via partnering or acquisition. In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards. | wan | |
27/7/2022 09:14 | Cambridgedon...As I allude to in post 211, it looks predominantly like a cash burn reduction exercise and a reflection of who can effectively lead Trellus in the current market, and perhaps more passionately lead and effectively deliver on the strategy, given the new CEO is a co-founder and has unrivalled expertise and reputation in Trellus Health's 'initial' market focus. We may get further clarification in Interim Results ended June 30th 2022. | wan | |
26/7/2022 16:08 | Does anyone know/have a theory as to why Monique Fayad went?? The share price has certainly bombed since the announcement. CD | cambridgedon | |
22/7/2022 09:11 | By my estimates, the shares are currently worth considerably less than the cash element i.e. cash is likely to be currently north of £20m and with a market cap under £15m. And one assumes, due to the recent announcement, that cash burn, which had already been carefully managed, has been further reduced. Although I am not sure what the prospects offer given those cut backs and indeed the market backdrop etc. | wan | |
22/7/2022 08:27 | 24p of shares traded market cap dropped by 5% over £800,000 corruption IMHO | senttothegallows | |
19/7/2022 08:52 | Still not showing properly within any of my Barclays accounts. I escalated this shambolic situation to an official complaint with Barclays 'many months' ago, as it also happened with Verici, which are still not registered in my accounts! I am pushing for 'definitive' answers on exactly why they have been unable to properly register the shares into my accounts. Chased it again last week, to include Trellus Health, they are still looking into the matters, implying it was complicated in defining who is at fault and why. | wan | |
18/7/2022 17:49 | Thanks adobbing. | cambridgedon | |
18/7/2022 17:26 | Mine showed up around the 24th June, in my ii ISA account | adobbing | |
18/7/2022 17:12 | A J Bell still not showing my in-specie shares! Anyone got them showing properly in their portfolios? CD | cambridgedon | |
12/7/2022 08:30 | Edit - link to correct article added in the above post | wan | |
12/7/2022 07:57 | We're thrilled to announce the official nationwide launch of Trellus Health for all people age 16+ in the US living with Crohn's disease and Ulcerative Colitis - Trellus Health appear to be in an area that may be somewhat 'differentiated' from the digital health crowd - Market downturn dampens digital health funding, M&A in 2022. These sectors raked in the most cash By Heather Landi Jul 12, 2022 "Venture investors raised record funds last year, meaning they will have capital to deploy for years to come," the researchers wrote. "Meanwhile, startups are using this market moment to reconsider valuations, trim costs, and, in some cases, people, and refine go-to-market strategies. We foresee these startup adjustments activating savvy M&A deal-makers in H2 2022, with pairings between complementary digital health companies likely leading H2 2022 M&A activity." Digital mental healthcare also continued to be a hot sector, raising a combined $1.3 billion in the first half of 2022 to again reach the top-funded clinical spot, led by Lyra’s $235 million raise in January. However, of that $1.3 billion just $300 million closed in Q2 2022—possibly signaling a slowdown. Full story - | wan | |
08/7/2022 08:46 | The Accidental GastroPsychologist: Building A Business From Behavior Support 07 Jul 2022 INTERVIEWS Executive Summary Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market. You need to sign up for a free trial to get access. | wan | |
06/7/2022 14:04 | It really is but the market is trading irrationally at the minute. These are in bargain territory | tommygunn21 | |
06/7/2022 12:03 | Valued significantly below cash absolute insanity IMHO | senttothegallows | |
01/7/2022 11:27 | Having watched the recent presentation and the fact they forecast profitability q4 next year and won't need to come back to the market. Currently valued at less than cash the ip and infrastructure is worth a significant amount. Too cheap imho | senttothegallows | |
29/6/2022 12:54 | By the time this dividend lands in my account I doubt it will even buy me a bowl of soup. | riddlerone | |
29/6/2022 07:59 | Digital Health Center of Excellence Updates from CDRH U.S. Food and Drug Administration sent this bulletin at 06/27/2022 June 27, 2022 Digital health is driving a revolution in health care, and the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) is helping set the stage for these advances. As an important step in promoting the advancement of digital health technology, CDRH established the Digital Health Center of Excellence (DHCoE). This update highlights DHCoE activities that promote awareness and consistent application of digital health regulatory policies to foster equity in health care; pioneer the development and enhancement of digital health regulatory paradigms; and cultivate digital health-focused collaborations. Discover how CDRH’s Digital Health Center of Excellence is helping set the stage for the advancement of digital health technologies to help protect and promote public health. | wan | |
25/6/2022 08:40 | First a quick summary/reminder - Trellus Health is a leading pioneer in validated resilience-driven care and the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health's digital-first chronic care management solution integrates convenient access to a licensed multidisciplinary care team with a suite of tools for resilience assessment, education and behavior modification, remote monitoring, health maintenance and prevention. Through its TrellusElevate&trade Thus, I found the following very interesting and encouraging - Telehealth visits for mental health continue to rise despite dropping in every other specialty Mental health is bucking the overall trend in telehealth utilization. A new report found that telehealth accounted for 87% of mental health appointments booked last month. That percentage is continuing to climb, despite virtual care visits declining across all other specialties. By KATIE ADAMS Jun 23, 2022 The explosive use of virtual care that occurred during the early months of the pandemic has dropped drastically across all specialties but one — mental health. In fact, telehealth utilization among mental health patients is continuing to climb, according to a new report. By contrast, when telehealth use for mental health appointments was examined, the numbers tell a different story. In May 2020, 74% of mental health appointments booked on Zocdoc were virtual. It rose to 85% in May 2021 and 87% in May 2022. Virtual mental health visits will continue to grow, said Richard Fine, Zocdoc’s chief commercial officer. He said that while every other specialty has shifted back to in-person care, mental health is pivoting even more toward telehealth. “The conversational nature of mental health appointments — and the discretion, ease and efficiency of talking to a therapist from home without a commute — means that telehealth is likely to remain patients’ first choice for mental health care,” he said. The Report referred to - | wan | |
24/6/2022 20:58 | @sharw My TRLS in specie shares have now appeared in my ISA account. I’m now the proud owner of 92 shares worth a grand total of £15.64 😂 | adobbing |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions